Ford L T
Clin Orthop Relat Res. 1977 Jan-Feb(122):367-73.
Clinical experience with Chymopapain casts doubts upon the reported results of the limited double blind studies done mainly by surgeons and their residents, relatively inexperienced in the disc injection technique. Chymopapain is a useful drug when used properly for lumbar disc disease and has the potential of eliminating three-fourths of lumbar disc surgery. Chymopapain should have been released by the FDA on a Phase IV basis. In the mean-time the drug is available in Canada and England but not in the U.S.
木瓜凝乳蛋白酶的临床经验对主要由外科医生及其住院医师进行的有限双盲研究报告的结果提出了质疑，他们在椎间盘注射技术方面相对缺乏经验。木瓜凝乳蛋白酶在正确用于治疗腰椎间盘疾病时是一种有用的药物，有可能减少四分之三的腰椎间盘手术。木瓜凝乳蛋白酶本应在FDA的IV期基础上获批。与此同时，该药物在加拿大和英国有供应，但在美国没有。
